A molecular prospective provides new insights into implication of PDYN and OPRK1 genes in alcohol dependence

Computers in Biology and Medicine

Volumn 53, Issue , 2014, Pages 250-257

  Faisal, Muhammad ^a   Waseem, Durdana ^a   Ismatullah, Humaira ^b   Taqi, Malik Mumtaz ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b INTERNATIONAL ISLAMIC UNIVERSITY   (Pakistan)

Author keywords

Alcohol addiction; Allele specific interactions; Prodynorphin (PDYN); Transcription factors; opioid receptor (OPRK1)

Indexed keywords

BINDING ENERGY; DNA; NUCLEOTIDES; PROTEINS; TRANSCRIPTION FACTORS;

ALCOHOL ADDICTION; DIFFERENTIAL REGULATION; DNA-PROTEIN INTERACTION; OPIOID RECEPTORS; PRODYNORPHIN (PDYN); SINGLE NUCLEOTIDE POLYMORPHISMS; SPECIFIC INTERACTION; SUSCEPTIBILITY DIFFERENCES; ALCOHOL DEPENDENCES;

TRANSCRIPTION; TRANSCRIPTION FACTORS;

ACTIN RELATED PROTEIN; CART 1 PROTEIN; CCAAT ENHANCER BINDING PROTEIN BETA; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; FARNESOID X RECEPTOR; KAPPA OPIATE RECEPTOR; NUCLEAR FACTOR Y; PRODYNORPHIN; RETINOID X RECEPTOR ALPHA; TATA BINDING PROTEIN RELATED FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F6; TRANSCRIPTION FACTOR GATA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR; UPSTREAM STIMULATORY FACTOR 2; ERBIUM; TRANSCRIPTION FACTOR; ENKEPHALIN; OPRK1 PROTEIN, HUMAN; PREPROENKEPHALIN; PROTEIN PRECURSOR; UNTRANSLATED REGION;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALCOHOLISM; ALLELE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; OPRK1 GENE; PDYN GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN INTERACTION; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISM; BIOLOGY; GENETIC DATABASE; GENETICS; METABOLISM; UNTRANSLATED REGION;

ALCOHOLISM; BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; ENKEPHALINS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PRECURSORS; RECEPTORS, OPIOID, KAPPA; TRANSCRIPTION FACTORS; UNTRANSLATED REGIONS;

EID: 84906736406     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2014.07.021     Document Type: Article

References (70)

1. Salari R., Kimchi-Sarfaty C., Gottesman M.M., Przytycka T.M. Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Res. 2013, 41(1):44-53.
2. De Gobbi M., Viprakasit V., Hughes J.R., Fisher C., Buckle V.J., Ayyub H., et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 2006, 312(5777):1215-1217.
3. Wassel C.L., Pankow J.S., Rasmussen-Torvik L.J., Li N., Taylor K.D., Guo X., et al. Associations of SNPs in ADIPOQ and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis (MESA). Obesity 2010, 19(4):840-847.
4. Xuei X., Dick D., Flury-Wetherill L., Tian H., Agrawal A., Bierut L., et al. Association of the κ-opioid system with alcohol dependence. Mol. Psychiatry 2006, 11(11):1016-1024.
5. Yang W., Wang Z., Zhu Y., Yang H. E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1. Cell Death Differ. 2006, 14(4):807-817.
6. Chang G.Q., Karatayev O., Ahsan R., Avena N.M., Lee C., Lewis M.J., et al. Effect of ethanol on hypothalamic opioid peptides, enkephalin, and dynorphin: relationship with circulating triglycerides. Alcohol Clin. Exp. Res. 2007, 31(2):249-259.
7. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997, 129(2):99-111.
8. Nylander I., Hyytiä P., Forsander O., Terenius L. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol Clin. Exp. Res. 1994, 18(5):1272-1279.
9. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 1983, 306:611-614.
10. Simmons S., Horowitz J. Nkx3.1 binds and negatively regulates the transcriptional activity of Sp-family members in prostate-derived cells. Biochem. J. 2006, 393:397-409.
11. Yuferov V., Fussell D., LaForge K.S., Nielsen D.A., Gordon D., Ho A., et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenet. Genomics 2004, 14(12):793-804.
12. Van Den Wildenberg E., Wiers R.W., Dessers J., Janssen R.G., Lambrichs E.H., Smeets H.J., et al. A functional polymorphism of the μ-opioid receptor Ggene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin. Exp. Res. 2007, 31(1):1-10.
13. Deb I., Chakraborty J., Gangopadhyay P.K., Choudhury S.R., Das S. Single nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 2010, 112(2):486-496.
14. Lappalainen J., Kranzler H.R., Malison R., Price L.H., Van Dyck C., Rosenheck R.A., et al. A functional neuropeptide Y leu7pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch. Gen. Psychiatry 2002, 59(9):825-831.
15. Shabalina S.A., Zaykin D.V., Gris P., Ogurtsov A.Y., Gauthier J., Shibata K., et al. Expansion of the human μ-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 2009, 18(6):1037-1051.
16. Kraus J., Borner C., Giannini E., Hickfang K., Braun H., Mayer P., et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J. Biol. Chem. 2001, 276(47):43901-43908.
17. Kraus J., Borner C., Giannini E., Hollt V. The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol. Pharmacol. 2003, 64(4):876-884.
18. Taqi M.M., Bazov I., Watanabe H., Nyberg F., Yakovleva T., Bakalkin G. Prodynorphin promoter SNP associated with alcohol dependence forms noncanonical AP-1 binding site that may influence gene expression in human brain. Brain Res. 2011, 1385:18-25.
19. Taqi M.M., Bazov I., Watanabe H., Sheedy D., Harper C., Alkass K., et al. Prodynorphin CpG-SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics. Addict. Biol. 2011, 16(3):499-509.
20. Cheng Y.C., Hsiao F.C., Yeh E.C., Lin W.J., Tang C.Y.L., Tseng H.-C., et al. VarioWatch: providing large-scale and comprehensive annotations on human genomic variants in the next generation sequencing era. Nucleic Acids Res. 2012, 40(W1):W76-W81.
21. Lee P.H., Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 2009, 25(8):1048-1055.
22. Wingender E., Chen X., Hehl R., Karas H., Liebich I., Matys V., et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res. 2000, 28(1):316-319.
23. Van Deventer S. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med. 2000, 26(1):S098-S102.
24. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 2004, 18(5):1109-1119.
25. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D3 and brain development. Neuroscience 2003, 118(3):641-653.
26. Mackay-Sim A., Féron F., Eyles D., Burne T., McGrath J. Schizophrenia, vitamin D, and brain development. Int. Rev. Neurobiol. 2004, 59:351-380.
27. Zakon H.H. The effects of steroid hormones on electrical activity of excitable cells. Trends Neurosci. 1998, 21(5):202-207.
28. Cornet A., Baudet C., Neveu I., Evercooren B.V., Brachet P., Naveilhan P. 1, 25-dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J. Neurosci. Res. 1998, 53(6):742-746.
29. Saporito M.S., Brown E.R., Hartpence K.C., Wilcox H.M., Vaught J.L., Carswell S. Chronic 1, 25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. Brain Res. 1994, 633(1):189-196.
30. Cartwright P., Mueller H., Wagener C., Holm K., Helin K. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene 1998, 17(5):611-623.
31. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001, 29(14):2905-2919.
32. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 2000, 74(5):311-317.
33. Porter W., Saville B., Hoivik D., Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11(11):1569-1580.
34. Lee W., Mitchell P., Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987, 49(6):741-752.
35. Wang W.-M., Wu S.-Y., Lee A.-Y., Chiang C.-M. Binding site specificity and factor redundancy in activator protein-1-driven human papillomavirus chromatin-dependent transcription. J. Biol. Chem. 2011, 286(47):40974-40986.
36. Rada-Iglesias A., Ameur A., Kapranov P., Enroth S., Komorowski J., Gingeras T.R., et al. Whole-genome maps of USF1 and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders. Genome Res. 2008, 18(3):380-392.
37. Chen B.K., Chang W.C. Functional interaction between c-Jun and promoter factor Sp1 in epidermal growth factor-induced gene expression of human 12 (S)-lipoxygenase. Proc. Natl. Acad. Sci. 2000, 97(19):10406-10411.
38. Chen P.H., Tsao Y.P., Wang C.C., Chen S.L. Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res. 2008, 36(1):51-66.
39. Cheng H.T., Chen J.Y., Huang Y.C., Chang H.C., Hung W.C. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J. Cell. Biochem. 2006, 98(6):1450-1456.
40. Datta P.K., Raychaudhuri P., Bagchi S. Association of p107 with Sp1: genetically separable regions of p107 are involved in regulation of E2F-and Sp1-dependent transcription. Mol. Cell. Biol. 1995, 15(10):5444-5452.
41. Safe S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 2001, 62:231-252.
42. Suske G. The Sp-family of transcription factors. Gene 1999, 238(2):291-300.
43. Yamada K., Osawa H., Granner D.K. Identification of proteins that interact with NF-YA. FEBS Lett. 1999, 460(1):41-45.
44. Satoh T., Ishizuka T., Tomaru T., Yoshino S., Nakajima Y., Hashimoto K., et al. Tat-binding protein-1 (TBP-1), an ATPase of 19S regulatory particles of the 26S proteasome, enhances androgen receptor function in cooperation with TBP-1-interacting protein/Hop2. Endocrinology 2009, 150(7):3283-3290.
45. Zhong S., Machida K., Tsukamoto H., Johnson D.L. Alcohol induces RNA polymerase III-dependent transcription through c-Jun by co-regulating TATA-binding protein (TBP) and Brf1 expression. J. Biol. Chem. 2011, 286(4):2393-2401.
46. Chen Y., Bates D.L., Dey R., Chen P.-H., Machado A.C.D., Laird-Offringa I.A., et al. DNA binding by GATA transcription factor suggests mechanisms of DNA looping and long-range gene regulation. Cell Rep. 2012, 2(5):1197-1206.
47. Pevny L., Simon M.C., Robertson E., Klein W.H., Tsai S.-F., D'Agati V., et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991, 349(6306):257-260.
48. Laverriere A.C., MacNeill C., Mueller C., Poelmann R.E., Burch J., Evans T. GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J. Biol. Chem. 1994, 269(37):23177-23184.
49. Ludlow L.B., Schick B.P., Budarf M.L., Driscoll D.A., Zackai E.H., Cohen A., et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibβ promoter resulting in the Bernard-Soulier syndrome. J.Biol. Chem. 1996, 271(36):22076-22080.
50. Ventura C., Zinellu E., Maninchedda E., Maioli M. Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells. Circ. Res. 2003, 92(6):623-629.
51. Kiefer F., Witt S., Frank J., Richter A., Treutlein J., Lemenager T., et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 2010, 11(5):368-374.
52. Bhinge A.A., Kim J., Euskirchen G.M., Snyder M., Iyer V.R. Mapping the chromosomal targets of STAT1 by sequence tag analysis of genomic enrichment (STAGE). Genome Res. 2007, 17(6):910-916.
53. Johnson D.S., Mortazavi A., Myers R.M., Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007, 316(5830):1497-1502.
54. Bakalkin G., Yakovleva T., Terenius L. The Leu-enkephalin-encoding sequence DNA-binding factor (LEF) is the transcription factor YY1. Biochem. Biophys. Res. Commun. 1997, 231(1):135-139.
55. Meberg P.J., Kinney W.R., Valcourt E.G., Routtenberg A. Gene expression of the transcription factor NF-κ B in hippocampus: regulation by synaptic activity. Mol. Brain Res. 1996, 38(2):179-190.
56. Zachariou V., Bolanos C.A., Selley D.E., Theobald D., Cassidy M.P., Kelz M.B., et al. An essential role for δFosB in the nucleus accumbens in morphine action. Nat. Neurosci. 2006, 9(2):205-211.
57. 2+-regulated transcriptional repressor. Nature 1999, 398:80-84.
58. Roder K., Wolf S., Larkin K., Schweizer M. Interaction between the two ubiquitously expressed transcription factors NF-Y and Sp1. Gene 1999, 234(1):61-69.
59. Becker D.M., Fikes J.D., Guarente L. A cDNA encoding a human CCAAT-binding protein cloned by functional complementation in yeast. Proc. Natl. Acad. Sci. 1991, 88(5):1968-1972.
60. Xu H., Fu J., Ha S.-W., Ju D., Zheng J., Li L., et al. The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes. BBA-Mol. Cell Res. 2012, 1823(4):818-825.
61. Yuferov V., Ji F., Nielsen D.A., Levran O., Ho A., Morgello S., et al. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology 2009, 34(5):1185-1197.
62. Bakalkin G., Watanabe H., Jezierska J., Depoorter C., Verschuuren-Bemelmans C., Bazov I., et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am. J. Hum. Genet. 2010, 87(5):593-603.
63. Ménard C., Herzog H., Schwarzer C., Quirion R. Possible role of dynorphins in Alzheimer[U+05F3]s disease and age-related cognitive deficits. Neurodegener. Dis. 2013, 13(2-3):82-85.
64. Sirohi S., Bakalkin G., Walker B.M. Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system. Front. Mol. Neurosci. 2012, 5:95.
65. Walker B.M., Valdez G.R., McLaughlin J.P., Bakalkin G. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol 2012, 46(4):359-370.
66. Lindholm S., Werme M., Brené S., Franck J. The selective κ-opioid receptor agonist U50, 488 H attenuates voluntary ethanol intake in the rat. Behav. Brain Res. 2001, 120(2):137-146.
67. Shippenberg T., Chefer V., Zapata A., Heidbreder C. Modulation of the behavioral and neurochemical effects of psychostimulants by κ-opioid receptor systems. Ann. N.Y. Acad. Sci. 2001, 937(1):50-73.
68. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Effect of the endogenous κ opioid agonist dynorphin A (1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6 J mice. Psychopharmacology 2004, 172(4):422-429.
69. Göndör A., Ohlsson R. Chromosome crosstalk in three dimensions. Nature 2009, 461(7261):212-217.
70. Babbitt C.C., Silverman J.S., Haygood R., Reininga J.M., Rockman M.V., Wray G.A. Multiple functional variants in cis modulate PDYN expression. Mol. Biol. Evol. 2010, 27(2):465-479.